Navigation Links
Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
Date:3/26/2013

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has signed a distribution agreement with MOSS S.p.A. of Italy.

The distribution agreement with MOSS covers the Tomophase product line including the OCT Imaging System, OCTIS™ and the OCTIS Probes in the territory Italy and San Marino. Upon signing, MOSS also purchased two systems for waiting Italian clinicians who are experts in pulmonary imaging. Delivery and installation of OCTIS is scheduled for June. These new systems for Italian medical centers follow the deployment and installation of OCTIS in Germany at the Thoraxklinik, University of Heidelberg.  Both MOSS and Tomophase will work together to expand the availability of this innovative and much anticipated technology to the Italian medical community. 

"We are delighted to have MOSS as our distributor in Italy. President Franco Papa and his team have been very active with innovative imaging technologies and have been following our progress at Tomophase. We look forward to close cooperation with MOSS as they extend our OCTIS technology for interventional pulmonology throughout Italy," said Ralph Johnston , President and CEO. 

Dr. Peter Norris , Tomophase Executive Chairman commented, "The partnership of Tomophase with Franco Papa and MOSS is another example of the high level of international interest in the OCTIS platform. With their experience in Interventional Pulmonology, MOSS is an excellent fit for OCTIS and our goal of introducing physicians to the greatly expanded pulmonary imaging capabilities it affords. The placement of OCTIS units in two major pulmonary centers in Italy is a major step forward in meeting this goal."

Mr. Franco Papa , MOSS President and CEO, personally expressed, "MOSS has specialized through the years in identifying high-tech, innovative solutions which may provide concrete answers to our end users' most specific therapeutic demands. Therefore we welcome the opportunity to partner with an outstanding company like Tomophase for the purpose of developing the national market by means of such a strategic collaboration and, thus, achieve a successful introduction of the Tomophase OCT Imaging System in the field."

About MOSS
MOSS was founded to further the idea of creating an active platform for young and dynamic companies in order to offer foreign-based advanced medical device manufacturers a local, operating interface to support their needs and requirements throughout Italy. 

About Tomophase
Tomophase is a leader in developing bronchoscopic-based systems for interventional pulmonology. Offering significantly higher resolution than either CT scan or ultrasound, OCTIS provides real-time, high resolution, sub-surface tissue imaging of airways and lungs, to be followed by diagnostic and therapeutic applications. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. The company has 28 patent and applications issued and pending. FDA 510(k) clearance for OCTIS was received and the CE Mark is expected in June. The U.S. commercial launch is underway and the EU rollout is proceeding. The company is currently raising investment capital to meet the increasing international demand for the OCT Imaging System.  Examples of our tissue imaging results are available at www.tomophase.com. For further information:In USA:Dr. Peter Norris, Executive Chairman 

Ralph Johnston, President, CEOTomophase CorporationTomophase CorporationP: (781) 229-57P: (781) 229-5700, ext 123 EmailEmailIn Italy: MOSS S.p.A.Via all'Erno, 528040 Lesa (NO) – ItalyTel. No.: +39 0322 772032Fax No.: +39 0322 292733EmailThis press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
2. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
3. Galderma, One of the Leading Pharmaceutical Companies, Relies on Verizon Enterprise Solutions to Provide Expanded, Secure Global Communications Platform
4. Torrance Memorial Medical Center Boosts Patient Safety With Expanded Use Of Capnography Technology
5. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
6. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
7. PET/MR Scanner Holds Promise For Expanded Diagnostics
8. BioElectronics Expands European Distribution to Malta
9. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Hyland Software and Merge Healthcare Expand Partnership to Provide Best of Breed ECM and VNA Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Abdominal Aortic Aneurysm Repair Devices Market was valued at $1,844 ... a CAGR of 5.1% from 2016 to 2022. The endovascular stent graft system segment ... during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... The global wound care market was worth $24,482.9 million in ... during 2016-2022 Among the various wound care products type, the ... market in 2015. Among the various applications, surgical wound segment held the ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... to the military at the same time by providing Prehospital Trauma Life Support ... PHTLS is the world’s premier prehospital trauma education developed in cooperation with the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... , ... The Radiology Business Management Association (RBMA) has named the ... their 12th year, are among the most prestigious in radiology marketing because a panel ... retooled to recognize achievements in both large budget (over $5,000) and small budget (under ...
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit ... business owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry ... , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged ...
Breaking Medicine News(10 mins):